4 completed, 1 recruiting, 1 terminated. 4 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow GEN-1: new trials by email Literature Review of GEN-1 trials Research Report on GEN-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-11-12 |
| Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer IMNN-001 - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Imunon | 18 | 2015-09-01 | 2024-10-02 |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 16 | 2012-07-09 | 2019-03-12 |
| EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1 - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 22 | 2010-11-01 | 2018-01-11 |
| Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms | Phase 1 | Completed | EGEN, Inc. | 13 | 2007-04-01 | 2013-03-26 |
| Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms | Phase 1 | Terminated | EGEN, Inc. | 18 | 2005-08-01 | 2013-02-28 |
Ovarian Neoplasms (5) · Fallopian Tube Neoplasms (4) · Carcinoma, Ovarian Epithelial (2)
EGEN, Inc. (2) · Gynecologic Oncology Group (2) · Imunon (2)
United States (6)
Premal H Thaker (1) · Premal H Thaker, M.D. (1) · Premal Thaker, M.D. (1) · Ronald Alvarez (1) · Ronald Alvarez, MD (1) · Ronald D. Alvarez, MD (1)
U10CA027469 (2), U10CA180868 (2)